Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin aspart 30 plus metformin versus insulin aspart 30 alone in type 2 diabetes after oral antidiabetic drug failure
ChiCTR-IPR-15006834Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Oct 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin aspart and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beijing Hospital. Primary endpoint: HbA1c change from baseline. Started Oct 2014; status: recruiting.
02
Drugs
insulin aspartmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-15006834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006834.